A renewed Board, new leadership, growing commercial momentum, and an exclusive focus on wound care have transformed Kane Biotech into a company built for growth. This is Kane 2.0.
Quarter Ended Jun 30, 2026
Since Spring 2025, Kane Biotech has reshaped every aspect of the business to support long-term value creation. A renewed Board of Directors, new executive leadership, experienced commercial talent, new strategic distribution and sales agreements, and an exclusive focus on human wound care have established a strong foundation for growth. Combined with an expanding body of clinical evidence, these changes reflect a company transformed and focused on executing its vision.
Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.
Sign up today and receive company updates straight to your inbox.
Kane Biotech Inc.
263-196 Innovation Drive
Winnipeg, MB R3T 6G2
Canada
T: (204) 453-1301
ir@kanebiotech.com
Kane Biotech Inc.
Phone: 204-453-1301
ir@kanebiotech.com
Canadian Stock Transfer Company Inc.
600, 333 – 7th Avenue S.W.
Calgary, Alberta T2P 2Z1
